Good news against cancer! Bedaquiline is effective in treating tuberculosis

Bedaquiline (Bedaquiline) can be used to treat multidrug-resistant tuberculosis. It is the world's first new anti-tuberculosis drug approved for the treatment of multidrug-resistant tuberculosis. Due to its unique mechanism of action, it has received widespread attention since its release. Multiple studies have confirmed that bedaquiline combined with conventional anti-tuberculosis drugs can significantly improve the success rate of treatment in the treatment of drug-resistant tuberculosis.

Bedaquiline can combine with ATP synthase oligomer subunit C, affecting the activity of the ATP synthase proton pump, causing ATP synthesis to be blocked, thus blocking the ATP energy supply in multi-drug-resistant tuberculosis and exerting antibacterial and bactericidal effects. Due to different mechanisms of action, bedaquiline has no cross-resistance with traditional anti-tuberculosis drugs and has strong antibacterial activity against sensitive strains, multidrug-resistant strains and dormant bacteria. But even though bedaquiline has a completely new mechanism of action, it cannot escape the development of resistance to MTB. Among the 90 XDR-TB strains in my country, the resistance rate to bedaquiline was 3.3%.

The drug is sold in China under the name of daquiline fumarate tablets and has been included in the scope of medical insurance. The price of a common specification of 100mg*24 tablets per box may be around 10,000 yuan, which is relatively expensive. The price of the Russian version of Bedaquiline sold overseas, Specifications100mg*188 tablets per box, may be around RMB 15,000 (the price may fluctuate due to the exchange rate). The pharmaceutical ingredients of Bedaquiline sold domestically and abroad are basically the same. Currently, there are no generic bedaquiline drugs produced and marketed overseas. For specific prices and drug information of overseas drugs, please consult Yaode Medical Consultant.